Social support networks of women in Naples

We present a measurement of the branching fraction of B⁺→ τ⁺ν_τ decays using (387 ± 6) × 106 ϒ(4S) events collected between 2019 and 2022 with the Belle II detector at the SuperKEKB e⁺e⁻ collider. We reconstruct the accompanying B⁻ meson using the hadronic tagging method, while B⁺→ τ⁺ν_τ candidates are identified in the recoil. We find evidence for B⁺→ τ⁺ν_τ decays at 3.0 standard deviations, including systematic uncertainties. The measured branching fraction is ℬ(B⁺ → τ⁺ν_τ) = [1.24 ± 0.41 (stat) ± 0.19 (syst)] × 10⁻⁴. Objective Cardiometabolic syndrome (CMS) increases risks for type 2 diabetes and cardiovascular disease. Although individual herbal extracts such as Panax ginseng, Panax notoginseng, and Salvia miltiorrhiza have demonstrated metabolic and cardiovascular benefits, their combined synergistic actions have not been comprehensively evaluated within an integrated preclinical framework. This study aimed to evaluate the efficacy of Deltan, a polyherbal formulation of Panax ginseng, Panax notoginseng, and Salvia miltiorrhiza, in mitigating CMS by modulating oxidative stress, lipid metabolism, inflammation, and gut microbiota. Methods A multi-tiered approach was employed, including UHPLC–HRMS metabolomic profiling, in silico molecular docking, in vitro antioxidant, lipase-inhibitory, and cardiomyoblast viability assays, and an eight-week randomized, controlled preclinical trial in Wistar rats fed a cholesterol- and fat-enriched diet. Evaluations included biochemical parameters, inflammatory mediators, and gut microbiota analysis via 16S rRNA sequencing. Results Deltan demonstrated potent antioxidant (IC₅₀ = 45.2 ± 2.3 µg/mL for DPPH scavenging) and lipase-inhibitory activities (IC₅₀ = 38.7 ± 1.9 µg/mL), effectively preserving H9c2 cardiomyoblast viability (89.6 ± 3.4 % at 100 µg/mL) and reducing PCSK9 (↓ 31 %) and Galectin-3 (↓ 27 %) secretion, comparable to simvastatin (↓ 35 % and ↓ 29 %, respectively). In vivo, Deltan prevented diet-induced weight gain (−18.4 % vs. CFED control), normalized serum lipids (total cholesterol ↓ 29 %, triglycerides ↓ 24 %, HDL ↑ 18 %) and glucose (↓ 22 %), attenuated hepatic stress markers (ALT and AST ↓ ~30 %), and regulated inflammatory and lipid-regulatory biomarkers including TNF-α (↓ 33 %), PCSK9 (↓ 36 %), ANGPTL3 (↓ 28 %), and PLA2G7 (↓ 25 %). Conclusion Deltan effectively targets multiple aspects of CMS through antioxidative, anti-inflammatory, lipid-regulatory, and microbiota-modulating mechanisms. These preclinical findings highlight its potential as a safe, multi-target phytotherapeutic intervention for CMS. Future studies should isolate active phytochemicals, elucidate detailed molecular pathways, and validate efficacy through clinical trials.